时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Despite recent progress in the field, clinical challenges including chemoresistance, recurrence, and metastasis remain major obstacles.；However, excessive autophagy can induce cancer cell death [, ].；However, to date, no studies have explored the role of MCOLN2 in breast cancer and its associated chemoresistance.
方法
Breast cancer specimens (excision/mastectomy specimens after chemotherapy) along with the corresponding clinical pathologic data from 44 patients were collected as described before [].；Tumor assessment was performed by haematoxylin and eosin (H&E) staining as a commonly used protocol for tumor diagnosis.；Immunohistochemistry staining for MCOLN2 was performed on human breast cancer tissue microarray specimens (HBreD140Su06, Xinchao, China), using the MCOLN2 antibody (1:400, Alomone labs).；The percentage of MCOLN2-positive cancer cells and the staining intensity grade (0–3) were determined.
核心结论
Immunoblots data confirmed the higher expression of MCOLN2 in MCF-7/ADM than in MCF-7 while MCOLN1 and MCOLN3 proteins remain unchanged.；Depletion of MCOLN2 significantly sensitized MCF-7/ADM cells to Adriamycin, resulting in reduced cell proliferation and decreased colony formation upon exposure to 2 µM Adriamycin (Fig.；D, MCOLN2 knockdown markedly increased intracellular drug levels, confirming that MCOLN2 regulates drug retention. ‖ 结论：These findings indicate that MCOLN2 may serve as a predictive biomarker in the development of personalized and precise treatment strategies and that MCOLN2 could be a treatment target to reverse chemotherapy resistance.
局限
全文未设独立 limitations 节；结构上为非 RCT 设计，因果推断强度受限。
对本项目的价值
★☆☆☆☆ 营养感知与自噬轴决定「干预窗口 + 剂量方案」，是组合疗法的时间锚。
全文来源
PMC JATS 全文（正文 32,060 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：MCOLN2 (Mucolipin-2) promotes autophagy to confer Adriamycin resistance in breast cancer by regulating mTOR degradation.
- 期刊与标识：Cell Oncol (Dordr) · PMID 42957906 · DOI 10.1007/s13402-026-01270-x
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。